scholarly article | Q13442814 |
P356 | DOI | 10.3109/07357907.2011.590569 |
P698 | PubMed publication ID | 21696295 |
P2093 | author name string | Steven M Sorscher | |
P433 | issue | 7 | |
P921 | main subject | trastuzumab | Q412616 |
P304 | page(s) | 456-459 | |
P577 | publication date | 2011-06-22 | |
P1433 | published in | Cancer Investigation | Q325953 |
P1476 | title | Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer | |
P478 | volume | 29 |
Q34483980 | Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients |
Q27027682 | Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis |
Q27853380 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial |
Q35863066 | Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification |
Q38694309 | FGFR2 Amplification in Colorectal Adenocarcinoma |
Q35195738 | FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival |
Q33979049 | HER-2 overexpression and survival in colorectal cancer: a meta-analysis |
Q36843773 | Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. |
Search more.